Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bacillus coagulans Hammer cell-free supernatant
- Development stage
- Preclinical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bacillus coagulans Hammer cell-free supernatant (CFS) is a postbiotic derivative consisting of the liquid medium remaining after the removal of Bacillus coagulans Hammer (often identified as strain ATCC 31284) cells. This supernatant contains a variety of bioactive secreted metabolites, including organic acids, bacteriocins, and extracellular vesicles. Preclinical research indicates that these components can exert antiproliferative and pro-apoptotic effects on human colorectal adenocarcinoma cell lines in vitro. The mechanism of action involves the modulation of apoptotic signaling pathways, such as the activation of caspases and the downregulation of anti-apoptotic proteins like Bcl-2, leading to programmed cell death in malignant cells. It is primarily investigated for its potential as a postbiotic or anticancer agent in the prevention and treatment of colorectal cancer.
- Other names
- Bacillus coagulans Hammer CFSB. coagulans Hammer cell-free supernatantBacillus coagulans Hammer culture supernatant
02
Targets
BCL-2 (BCL-2 family)CASP9 (Caspase-9)CASP3 (Caspase-3)
Beyond the preview
Go deeper on Bacillus coagulans Hammer cell-free supernatant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bacillus coagulans Hammer cell-free supernatant.